Latest Health News

Thrive Tribe Technologies reported a $451,000 net operating cash outflow in Q1 FY26 but bolstered its cash reserves to $589,000 through over $1 million in equity placements. The company progressed its Thrive Tribe Home Base initiative and expanded its digital business units while managing a limited cash runway.

Cleo Diagnostics has secured positive FDA feedback and nearly 1,600 biobank samples, accelerating its ovarian cancer blood test development ahead of a planned 2026 U.S. market entry.

HeraMED has bolstered its cash position with a $1.98 million capital raise and is on the cusp of finalizing two pivotal U.S. commercial agreements, signaling a major step forward for its digital maternity care platform.

BPH Global Limited secured $1.1 million in a recent placement and reported robust growth in its Indonesian seaweed operations, alongside promising advances in innovative seaweed-based products and strategic regional partnerships.

WA Kaolin Ltd has reported a record-breaking quarter in sales volume and revenue, driven by operational enhancements and expanding market reach across Asia and domestic sectors.

Burgundy Diamond Mines reported a robust A$80.4 million net cash inflow from operations in Q3 2025, offset by significant capital expenditure on its Point Lake project and ongoing loan repayments.

McPherson’s Limited updates shareholders on its ongoing transformation journey, reporting modest core brand growth in FY25 and outlining a strategic outlook for FY26 focused on sustainable expansion and operational efficiency.

Spenda Limited reported a record $204 million in payment volumes for Q1 FY26 alongside a strategic cost reduction of 21% annualised. The quarter also saw a significant leadership change with the resignation of its Managing Director.

Nexsen Limited has successfully completed an $8 million IPO and ASX listing, while advancing its kidney diagnostic tests and initiating clinical trials for its GBS Rapid Sensor targeting expedited FDA approval.

EVE Health Group has taken significant strides in commercialising its women’s and men’s health products Dyspro™ and Libbo™, securing regulatory clearances, first patient prescriptions, and raising $1.1 million to support market expansion.

Vitasora Health Limited reported robust patient program growth and secured new US partnerships, driving revenue above A$1 million for the quarter. A recent A$11 million capital raise positions the company for continued expansion and cash-flow breakeven by late 2026.

True North Copper reported significant copper-gold and copper-cobalt-silver discoveries in its September 2025 quarter, reinforcing its growth strategy and financial strength heading into 2026.